Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Kangpu Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kangpu Biopharmaceuticals Initiates Phase Ib\/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GREECE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kangpu Biopharmaceuticals"},{"company":"Kangpu Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES\u2122 Molecular Glue KPG-818 in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GREECE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kangpu Biopharmaceuticals"}]

Kangpu Biopharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus

Details:

KPG-818 is novel cereblon E3 ubiquitin ligase complex modulator for treatment of autoimmune diseases and hematologic malignancies, demonstrated good tolerability, a favorable pharmacokinetic profile, and substantial potency for the degradation of Ikaros and Aiolos.

Lead Product(s): KPG-818

Therapeutic Area: Immunology Product Name: KPG-818

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 13, 2022

ASK
US

Upload
your Pipeline Activity

Kangpu Biopharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus

Details:

The Phase Ib/IIa multicenter, randomized, double-blind, placebo-controlled clinical study will evaluate the safety and tolerability, pharmacokinetics and preliminary efficacy of KPG-818 in patients with mild to moderate SLE.

Lead Product(s): KPG-818

Therapeutic Area: Immunology Product Name: KPG-818

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 16, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY